Wearables To Improve R&D Of CNS Diseases
The global central nervous system drugs market was valued at around $71 billion in 2017. North America was the largest region in the central nervous system drugs market in 2017, accounting for nearly 40% market share. The USA was the largest country in th
(EMAILWIRE.COM, November 16, 2018 ) Pharmaceutical companies are partnering with technology companies and incorporating wearables in clinical studies and for research and development of CNS disease treatments. These wearable devices make use of sensors to detect early symptoms of Parkinson’s disease such as tremors, slowness and stiffness in patients. Researchers use this data to gain insights about the disease and potential drug reactions, and thus reduce the time for trials by 30% to 50%. For instance, in 2016, Michael J. Fox Foundation for Parkinson’s Research collaborated with specialty drug maker Cynapsus Therapeutics and Intel to integrate wearable technology in a Phase-III clinical trial of APL-130277, an experimental drug for Parkinson’s disease. Biogen, a leading CNS drug maker is using Fitbit, a smart wearable tracker, to better understand multiple sclerosis in patient studies, and the technology is expected to extend in Alzheimer’s disease research.
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET TO GROW TO $88 BILLION BY 2021
North America was the largest region in the central nervous system drugs market in 2017, accounting for almost two-fifth of the market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs.
Order the report at https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2018
According to The Business Research Company’s Consultant, Nitin Gianchandani, regenerative therapies for the treatment of central nervous system diseases is one of the emerging trends in the global central nervous system drugs market. CNS diseases such as Alzheimer’s, Parkinson’s disease, spinal cord injury and optic neuropathies are complex disorders and cannot be completely cured by current therapeutic strategies, hence facilitating the need for regenerative therapies. Regenerative therapies are medications that replace, engineer or regrow damaged cells to treat a particular disease. These therapies help in the healing process by regenerating human cells, tissues, and organs. Major regenerative therapies include transplantation by embryonic stem cells, usage of matrix such as fibrin, collagen, and hyaluronic acid.
Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=279&type=smp
Biogen Inc. was the largest company in the CNS drugs market in 2017, with revenues of $8.3 billion in 2016. Biogen Idec’s growth strategy is to develop and expanding its neurology portfolio. In this regard, the company acquired UK-based clinical-stage biopharmaceutical company Convergence Pharmaceuticals, in January 2015. Convergence Pharmaceuticals offers ion channel-modulating products that can be used to treat neuropathic pain. In addition, with sales of its drugs growing in the US, Biogen Idec is expanding its manufacturing capacity in the country. In February 2015, the company added 100 more employees to its plant in Research Triangle Park, North Carolina.
The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.
Central Nervous System Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
THE BUSINESS RESEARCH COMPANY EXPECTS THE GLOBAL CENTRAL NERVOUS SYSTEM DRUGS MARKET TO GROW TO $88 BILLION BY 2021
North America was the largest region in the central nervous system drugs market in 2017, accounting for almost two-fifth of the market share. This can be attributed to high per capita spending on drugs to treat central nervous system disorders, the aging population and the insurance system which supports high healthcare costs.
Order the report at https://www.thebusinessresearchcompany.com/report/central-nervous-system-drugs-global-market-report-2018
According to The Business Research Company’s Consultant, Nitin Gianchandani, regenerative therapies for the treatment of central nervous system diseases is one of the emerging trends in the global central nervous system drugs market. CNS diseases such as Alzheimer’s, Parkinson’s disease, spinal cord injury and optic neuropathies are complex disorders and cannot be completely cured by current therapeutic strategies, hence facilitating the need for regenerative therapies. Regenerative therapies are medications that replace, engineer or regrow damaged cells to treat a particular disease. These therapies help in the healing process by regenerating human cells, tissues, and organs. Major regenerative therapies include transplantation by embryonic stem cells, usage of matrix such as fibrin, collagen, and hyaluronic acid.
Download a sample of the report at https://www.thebusinessresearchcompany.com/sample.aspx?id=279&type=smp
Biogen Inc. was the largest company in the CNS drugs market in 2017, with revenues of $8.3 billion in 2016. Biogen Idec’s growth strategy is to develop and expanding its neurology portfolio. In this regard, the company acquired UK-based clinical-stage biopharmaceutical company Convergence Pharmaceuticals, in January 2015. Convergence Pharmaceuticals offers ion channel-modulating products that can be used to treat neuropathic pain. In addition, with sales of its drugs growing in the US, Biogen Idec is expanding its manufacturing capacity in the country. In February 2015, the company added 100 more employees to its plant in Research Triangle Park, North Carolina.
The central nervous system drugs market includes medications that are used in the treatment of diseases affecting the brain or spinal cord. The central nervous system (CNS) integrates sensory information and instructs the body to respond accordingly. The spinal cord is a channel for signals between the brain and the rest of the body. Central nervous system (CNS) disorder is a condition in which the brain and spinal cord’s ability to function is affected, hence affecting the body. The market for CNS disorder drugs comprises of drugs that work in different ways depending on the type of disease by suppressing or boosting the brain activities. Top selling neurological drugs in 2016 include Copaxone, Lyrica, and Tecfidera.
Central Nervous System Drugs Global Market Report 2018 is a detailed report giving a unique insight into this market. The report is priced at $4000 for an individual user. To use across your office, the price is $6000 and $8000 if you wish to use across a multinational company.
About The Business Research Company
Visit TheBusinessResearchCompany.com, mail info@tbrc.info or call +447443439350 or +918897263534 or +919160996838 for more information on this and many other titles.
The Business Research Company is a market research and intelligence company, which excels in company, market and consumer research.
It has research professionals at its offices in the UK, India and the US as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, chemicals and technology.
The Business Research Company's management has more than 20 years of varied business research experience. They have delivered hundreds of research projects to the senior management of some of the world's largest organizations
Contact Information.
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Linkedin: https://in.linkedin.com/company/the-business-research-company
Contact Information:
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
The Business Research Company
Marketing TBRC
Tel: +91 8897263534
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results